We are live on ! Find out more
DCM

DAFNA Capital Management Portfolio holdings

AUM $440M
1-Year Est. Return 109.12%
This Fund
S&P 500
This Quarter Est. Return
+13.9%
1 Year Est. Return
+109.12%
3 Year Est. Return
+239.59%
5 Year Est. Return
+227.89%
10 Year Est. Return
+3,611.91%
AUM
$366M
AUM Growth
+$32.2M
Cap. Flow
+$2.36M
Cap. Flow %
0.64%
Top 10 Hldgs %
49.41%
Holding
80
New
7
Increased
18
Reduced
15
Closed
7

Top Buys

Rank Stock Value
1
DAWN
Day One Biopharmaceuticals
DAWN
+$6.62M
2
TSVT
2seventy bio
TSVT
+$5.26M
3
TNDM icon
Tandem Diabetes Care
TNDM
+$3.54M
4
KURA icon
Kura Oncology
KURA
+$2.93M
5
MRUS
Merus
MRUS
+$2.21M

Top Sells

Rank Stock Value
1
KRTX
Karuna Therapeutics, Inc. Common Stock
KRTX
+$7.8M
2
CSII
Cardiovascular Systems, Inc.
CSII
+$5.7M
3
APLS
Apellis Pharmaceuticals
APLS
+$3.81M
4
BHVN icon
Biohaven
BHVN
+$3.69M
5
DICE
DICE Therapeutics, Inc. Common Stock
DICE
+$2.07M

Sector Composition

Rank Sector Weight
1 Healthcare 82.6%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RCUS icon
26
Arcus Biosciences
RCUS
$3.48B
$4.58M 1.25%
225,717
+50,500
+29% +$962K
IPSC icon
27
Century Therapeutics
IPSC
$355M
$4.13M 1.13%
1,307,407
– –
EWTX icon
28
Edgewise Therapeutics
EWTX
$4.08B
$4.03M 1.1%
519,384
-213,855
-29% -$1.8M
BCRX icon
29
BioCryst Pharmaceuticals
BCRX
$2.24B
$4.01M 1.1%
569,000
+17,500
+3% +$140K
ALEC icon
30
Alector
ALEC
$168M
$3.84M 1.05%
638,938
+46,500
+8% +$325K
KURA icon
31
Kura Oncology
KURA
$804M
$3.79M 1.04%
357,784
+248,000
+226% +$2.93M
MRTX
32
DELISTED
Mirati Therapeutics, Inc. Common Stock
MRTX
$3.42M 0.94%
94,700
+21,100
+29% +$869K
BCYC
33
Bicycle Therapeutics
BCYC
$271M
$3.12M 0.85%
122,200
– –
AXGN icon
34
Axogen
AXGN
$2.46B
$3.03M 0.83%
332,103
– –
MDWD icon
35
MediWound
MDWD
$181M
$2.75M 0.75%
257,653
– –
TNDM icon
36
Tandem Diabetes Care
TNDM
$1.39B
$2.7M 0.74%
+110,000
New +$3.54M
MRSN
37
DELISTED
Mersana Therapeutics
MRSN
$2.67M 0.73%
32,434
+11,999
+59% +$1.76M
AUTL
38
Autolus Therapeutics
AUTL
$500M
$2.21M 0.61%
930,394
-245,756
-21% -$583K
LKFT
39
Lakefront Biotherapeutics American Depositary Shares
LKFT
$1.75B
$2.14M 0.59%
52,675
– –
ACET icon
40
Adicet Bio
ACET
$86M
$1.94M 0.53%
49,816
– –
KROS icon
41
Keros Therapeutics
KROS
$199M
$1.92M 0.52%
47,661
+28,300
+146% +$1.24M
RGLS
42
DELISTED
Regulus Therapeutics
RGLS
$1.63M 0.45%
1,111,049
+555,494
+100% +$740K
VIGL
43
DELISTED
Vigil Neuroscience
VIGL
$1.62M 0.44%
172,308
– –
PRQR icon
44
ProQR Therapeutics
PRQR
$243M
$1.52M 0.42%
940,582
– –
LYRA
45
DELISTED
LYRA THERAPEUTICS INC
LYRA
$1.48M 0.41%
+7,222
New +$1M
MREO
46
Mereo BioPharma
MREO
$53.2M
$1.33M 0.36%
1,009,013
-87,500
-8% -$101K
ITOS
47
DELISTED
iTeos Therapeutics
ITOS
$1.3M 0.36%
98,560
– –
BWAY
48
Brainsway
BWAY
$631M
$1.15M 0.31%
1,009,362
+61,400
+6% +$55K
STRO icon
49
Sutro Biopharma
STRO
$410M
$1.13M 0.31%
24,278
+15,808
+187% +$787K
LRMR icon
50
Larimar Therapeutics
LRMR
$402M
$1.1M 0.3%
350,373
+113,500
+48% +$463K
1
2
3 4

Similar funds

CDMG
Creek Drive Management Group San Francisco, California $439M AUM
STCG
Speece Thorson Capital Group Minnetonka, Minnesota $439M AUM 10.15% 1-Year Est. Return
SCP
SailingStone Capital Partners Houston, Texas $440M AUM 127.21% 1-Year Est. Return
CAAM
Cape Ann Asset Management London, United Kingdom $440M AUM 96.23% 1-Year Est. Return
HCM
Harvey Capital Management Palm Beach, Florida $439M AUM 37.68% 1-Year Est. Return
BOA
Birnam Oak Advisors New York $441M AUM 37.12% 1-Year Est. Return
ECA
Endeavour Capital Advisors Greenwich, Connecticut $441M AUM 21.38% 1-Year Est. Return
WAS
Winch Advisory Services Appleton, Wisconsin $438M AUM 17.59% 1-Year Est. Return

DAFNA Capital Management's Q2 2023 Portfolio in Review

As of Q2 2023, DAFNA Capital Management held 80 positions worth $366M, up 9.7% from $334M the previous quarter. Its ten largest holdings account for 49% of the portfolio.

DAFNA Capital Management's Q2 2023 filing shows 7 new, 18 increased, 15 reduced and 7 closed positions. Its largest new stake was Day One Biopharmaceuticals: 507,100 shares worth $6.05M. The largest sale was Karuna Therapeutics, Inc. Common Stock, an estimated $7.8M.

By sector, the portfolio is most concentrated in Healthcare at 83% of assets, up from 81% a quarter earlier.

  • DAFNA Capital Management's largest Q2 2023 buy was Day One Biopharmaceuticals: 507,100 shares worth $6.05M.
  • DAFNA Capital Management added most to Kura Oncology in Q2 2023, an estimated $2.93M increase.
  • DAFNA Capital Management's biggest Q2 2023 reduction was Karuna Therapeutics, Inc. Common Stock, cutting an estimated $7.8M.
  • DAFNA Capital Management fully exited Cardiovascular Systems, Inc. in Q2 2023, selling an estimated $5.7M.
  • DAFNA Capital Management's ten largest holdings make up 49% of its $366M portfolio in Q2 2023.
  • DAFNA Capital Management opened 7 new positions and closed 7 in Q2 2023.
  • DAFNA Capital Management's portfolio value rose 9.7% quarter-over-quarter to $366M.

Based on DAFNA Capital Management's 13F filing for Q2 2023, filed 14 Aug 2023.